NCT04867187

Brief Summary

Neuropathic pain is particularly difficult to treat with classic first-line drugs. Neuromodulation techniques using repetitive transcranial magnetic stimulation (rTMS) are useful alternative, but there is a need to improve their analgesic effect.Virtual reality mirror therapy has shown the capacity to alleviate pain and may be easily coupled with rTMS.The present project will investigate in individuals with neuropathic pain the effects of the rTMS coupled with virtual reality mirror therapy.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
11mo left

Started Oct 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress81%
Oct 2022Apr 2027

First Submitted

Initial submission to the registry

April 27, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 30, 2021

Completed
1.5 years until next milestone

Study Start

First participant enrolled

October 27, 2022

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2027

Last Updated

May 8, 2026

Status Verified

May 1, 2026

Enrollment Period

4.1 years

First QC Date

April 27, 2021

Last Update Submit

May 5, 2026

Conditions

Keywords

transcranial magnetic stimulationvirtual realitymirror therapybrain networkspredictive model

Outcome Measures

Primary Outcomes (1)

  • Pain intensity measurement

    Averages of the daily visual analogue scale scores (min no pain max pain imaginable) measured during the first week (Week 1) and that measured during the week following the last session (week 9)

    Week 9

Secondary Outcomes (4)

  • Quality of life after treatment

    week 12

  • Spontaneous brain activity

    week 12

  • neuropathic dimension

    Week 3, 5, 7, 9,12

  • Adverse events

    Week 3, 5, 7, 9,12

Study Arms (2)

rTMS active and active mirror-based therapy using virtual reality

EXPERIMENTAL

The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and active mirror-based therapy using virtual reality.

Other: Repetitive transcranial magnetic stimulation (rTMS)Other: Mirror therapy using virtual reality

rTMS active and sham mirror-based therapy using virtual reality

SHAM COMPARATOR

The patient will have an amount of 4 sessions (S3, S5, S7 and S9) for 1.5 months: 1 session every 2 weeks. The patient will receive rTMS active and sham mirror-based therapy using virtual reality.

Other: Repetitive transcranial magnetic stimulation (rTMS)Other: Mirror therapy using sham mirror

Interventions

20 minutes of high frequency (20Hz) rTMS.

rTMS active and active mirror-based therapy using virtual realityrTMS active and sham mirror-based therapy using virtual reality

active mirror-based therapy

rTMS active and active mirror-based therapy using virtual reality

20 minutes of sham mirror-based therapy

rTMS active and sham mirror-based therapy using virtual reality

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical symptoms typical of neuropathic pain
  • Refractory to drug therapies
  • Lasting for at least 6 months, with a moderate to severe pain intensity (≥4/10 on Visual Analog Scale, VAS) and a stable pain treatment since 1month at least
  • Having right to health benefits

You may not qualify if:

  • Ferromagnetic components and implanted microprocessors (i.e. cochlear implants)
  • Drug-resistant or active epilepsy, pacemaker, pregnancy, ongoing depression or personality troubles, and ongoing opioid treatment.
  • Any other contraindications to MRI scanner (e.g., claustrophobia, etc.).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hôpital Neurologique Pierre Wertheimer

Bron, 69500, France

NOT YET RECRUITING

Centre Hospitalier Universitaire de Saint-Etienne

Saint-Etienne, 42055, France

RECRUITING

MeSH Terms

Conditions

Neuralgia

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Peripheral Nervous System DiseasesNeuromuscular DiseasesNervous System DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Officials

  • Roland Peyron, MDPHD

    CENTRE HOSPITALIER DE SAINT-ETIENNE

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Beatrice DEYGAS, CRA

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
The (motor) task performed by the patient during the sham control mirror therapy session is identical to that performed in active mirror therapy. The only difference is that in sham mirror therapy there is no optical illusion of movement of the affected hand.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Group 1: patient with 4 sessions of active mirror therapy followed by an rTMS stimulation session of the primary motor cortex (M1), Group 2: patient with 4 sessions of sham mirror therapy followed by rTMS of the primary motor cortex (M1).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 27, 2021

First Posted

April 30, 2021

Study Start

October 27, 2022

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

April 1, 2027

Last Updated

May 8, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations